Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.18
(1.67%)
HKD 0.18
(1.67%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 24.62 Million CNY | -2.77% |
| 2022 | 25.33 Million CNY | -3.05% |
| 2021 | 26.12 Million CNY | 18.94% |
| 2020 | 21.96 Million CNY | -13.76% |
| 2019 | 25.47 Million CNY | -11.18% |
| 2018 | 28.67 Million CNY | 8.05% |
| 2017 | 26.54 Million CNY | 4.45% |
| 2016 | 25.41 Million CNY | 30.6% |
| 2015 | 19.45 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 5.95 Million CNY | -13.07% |
| 2024 Q2 | 5.95 Million CNY | 0.0% |
| 2023 Q2 | 5.7 Million CNY | -0.99% |
| 2023 Q4 | 6.85 Million CNY | 8.65% |
| 2023 Q1 | 5.76 Million CNY | -12.43% |
| 2023 Q3 | 6.3 Million CNY | 10.61% |
| 2023 FY | 24.62 Million CNY | -2.77% |
| 2022 Q2 | 5.89 Million CNY | -0.05% |
| 2022 Q1 | 5.9 Million CNY | -21.94% |
| 2022 FY | 25.33 Million CNY | -3.05% |
| 2022 Q3 | 6.95 Million CNY | 17.92% |
| 2022 Q4 | 6.57 Million CNY | -5.39% |
| 2021 Q4 | 7.55 Million CNY | 18.15% |
| 2021 FY | 26.12 Million CNY | 18.94% |
| 2021 Q3 | 6.39 Million CNY | -12.18% |
| 2021 Q2 | 7.28 Million CNY | 49.02% |
| 2021 Q1 | 4.88 Million CNY | -37.87% |
| 2020 Q4 | 7.86 Million CNY | 14.18% |
| 2020 Q3 | 6.89 Million CNY | 33.75% |
| 2020 Q2 | 5.15 Million CNY | 150.58% |
| 2020 Q1 | 2.05 Million CNY | -70.87% |
| 2020 FY | 21.96 Million CNY | -13.76% |
| 2019 Q4 | 7.05 Million CNY | 4.18% |
| 2019 Q3 | 6.77 Million CNY | 3.21% |
| 2019 Q2 | 6.56 Million CNY | 29.46% |
| 2019 FY | 25.47 Million CNY | -11.18% |
| 2019 Q1 | 5.07 Million CNY | -33.52% |
| 2018 Q3 | 7.68 Million CNY | 4.13% |
| 2018 Q4 | 7.62 Million CNY | -0.74% |
| 2018 FY | 28.67 Million CNY | 8.05% |
| 2018 Q2 | 7.38 Million CNY | 23.33% |
| 2018 Q1 | 5.98 Million CNY | 0.0% |
| 2017 FY | 26.54 Million CNY | 4.45% |
| 2016 FY | 25.41 Million CNY | 30.6% |
| 2015 FY | 19.45 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | 90.497% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 99.766% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | 58.325% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | 96.858% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | 97.438% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | 97.661% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | 98.557% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | 96.956% |
| PuraPharm Corporation Limited | 406.85 Million HKD | 93.947% |
| SSY Group Limited | 6.46 Billion HKD | 99.619% |
| JBM (Healthcare) Limited | 648.41 Million HKD | 96.202% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | 98.322% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.991% |